Promising combo for eye cancer stalls after only 3 patients enrolled
NCT ID NCT03712904
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This phase II trial tested a combination of precise radiation therapy followed by injections of aflibercept (Eylea) in people with uveal melanoma, a rare eye cancer. The goal was to see if this approach could control the tumor while reducing side effects like swelling or damage to the retina. However, the study was terminated early after enrolling only 3 participants, so we have very little data to draw conclusions from.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
aflibercept (Eylea) and stereotactic body radiation therapy
What this could lead to
If successful, this combination could offer a new way to control uveal melanoma while reducing damage to healthy eye tissue.
What could go wrong
This was a very small, early-phase trial that was terminated early with only 3 participants, so results are extremely limited and may not apply to others.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for UVEAL MELANOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Sidney Kimmel Cancer Center at Thomas Jefferson University
Philadelphia, Pennsylvania, 19107, United States